Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth more than offsetting pricing weakness and currency headwinds. The $1.2 billion Dermavant acquisition appears strategically acceptable but carries significant risks due to market competition and OGN's high debt.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Organon & Co. (OGN) Q3 2024 Earnings Call Transcript
Organon & Co. (NYSE:OGN ) Q3 2024 Earnings Call Transcript October 31, 2024 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Walsh - CFO Conference Call Participants Balaji Prasad - Barclays David Amsellem - Piper Sandler Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Operator Thank you for standing by. My name is Mandeep and I'll be your operator today.
Organon (OGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Organon (OGN) Q3 Earnings and Revenues Beat Estimates
Organon (OGN) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.87 per share a year ago.
Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Organon (OGN) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Earnings Preview: Organon (OGN) Q3 Earnings Expected to Decline
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here's Why Organon (OGN) Gained But Lagged the Market Today
In the closing of the recent trading day, Organon (OGN) stood at $18.10, denoting a +0.56% change from the preceding trading day.
Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Organon (OGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to Know
Organon (OGN) closed at $18.10 in the latest trading session, marking a -0.11% move from the prior day.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
